Redeye returns with more flesh on the bone regarding the Q4 report. While strong Fx tailwinds boosted the EBIT beat, we overlook our OPEX assumptions and update our WACC to 8% (9%). We raise our fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

BONESUPPORT Q4 - Operating leverage set to accelerate